Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
India had proposed for setting up the global standards for millets
The product has been in-licensed from Strides and will be commercialized by Amneal
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Subscribe To Our Newsletter & Stay Updated
